Maybe back in the saddle? Here's today's news!
---------------------------------------------------
Monday June 15, 9:31 am Eastern Time
Company Press Release
SOURCE: Biosonics, Inc.
Medicare Withdraws Non-Coverage Notice of the Salitron(R),
Biosonics Plans for Marketing
This Release is as a Clarification of the Previous Press Release Dated June 2, 1998
FT. WASHINGTON, Pa., June 15 /PRNewswire/ -- Biosonics, Inc. (OTC Bulletin Board: BISN - news) announces
that Medicare withdrew its non-coverage reimbursement of the Salitron in a Federal Register Notice, dated June 1,
1998. They had previously published a notice in the Federal Register on May 23, 1994, that they were not going to
reimburse Medicare patients for the purchase of the Salitron. Medicare is now reassessing the Salitron System,
primarily based on new data submitted by Biosonics, and Biosonics expects a determination soon. This withdrawal
enables the four regional carriers to individually determine coverage in their regions.
The Salitron System which is approved for marketing by the FDA, counteracts dry mouth, as a result of Sjogren's
syndrome. Dry mouth is much more debilitating than most realize and affects more than 1 million people. A dry mouth
sufferer cannot swallow, talk, or taste. Their teeth and gums decay, and their tongue burns. In addition, they can not
sleep without getting up frequently to lubricate their mouth, otherwise their tongue will stick to the roof of their mouth.
Although it doesn't kill directly, it devastates their ''quality of life.'' Sjogren's syndrome is a progressive disease, so
many people don't experience its full impact until they reach their senior years. Reimbursement by Medicare for use of
the Salitron would help restore their ''quality of life.'' Biosonics has been reimbursed by approximately 46 private
carriers, HMO's and Medicaid.
In light of this new development, Biosonics is proceeding with the marketing of the Salitron system. Approximately
500 doctors have used the Salitron for testing/prescribing. Biosonics intends to begin a sales campaign that will include
contacting doctors to help generate Salitron sales.
Biosonics has developed three other products that are approved for marketing by the FDA. The
CYSTOTRON(TM), urinary incontinence; the ANOTRON(TM), fecal incontinence; and the BIDDS(TM) GLOVE
a diagnostic tool to be used by the physician to predetermine the effectiveness of the Cystotron or Anotron, as well as
the degree of incontinence. Biosonics is planning to manufacture and market these devices through the development of
a 500 person market study, and contacting distributors for the distribution of the BIDDS Glove to hospitals, for use in
diagnosing incontinence.
For further information, please contact Jack Paller at 215-646-7100 or visit their web site at www.biosonics.com.
SOURCE: Biosonics, Inc.
|
